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  A b s t r a c t
   Background:  High levels of alkaline phosphatase (ALP) have been associated with increased 
mortality in patients with advanced chronic kidney disease (CKD). We hypothesize that elevat-
ed ALP could be partly explained by subclinical liver congestion related to left ventricular dia-
stolic dysfunction.   Methods:  Doppler echocardiography was performed in 68 patients with 
advanced CKD followed up for a median of 2.1 years. Time-averaged levels of ALP and      -glu-
tamyl transferase (GGT) were compared between patients with and without diastolic dysfunc-
tion. We also evaluated the effect of intensifying diuretic treatment on ALP levels in a small 
group of 16 patients with high ALP and signs of volume overload.  Results:  ALP correlated sig-
nificantly (p   !   0.001) with GGT but not with parathyroid hormone (p = 0.09). Patients with dia-
stolic dysfunction showed higher ALP (p = 0.01), higher GGT (p = 0.03) and lower albumin (p = 
0.04). The highest values of ALP were observed in patients with diastolic dysfunction plus pul-
monary hypertension (p = 0.01). Intensifying diuretic therapy in a subgroup of patients with 
signs of fluid overload induced a significant reduction in body weight, GGT (p  !   0.001) and ALP 
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levels (p   !   0.001).   Conclusions:  Elevated ALP in patients with advanced CKD could be partly 
explained by subclinical liver congestion related to left ventricular diastolic dysfunction, hy-
pervolemia or both. The worse prognosis of these patients could be explained by their myo-
cardial damage.     Copyright © 2012 S. Karger AG, Basel
  Introduction
    Left ventricular (LV) diastolic dysfunction, related to LV hypertrophy and myocardial 
fibrosis, is highly prevalent among patients with chronic kidney disease (CKD)   [1, 2]   and its 
prevalence and severity increases in parallel with the severity of CKD   [3, 4]  .
  The pathophysiology of diastolic dysfunction includes delayed relaxation resulting in an 
upward displacement of the diastolic pressure-volume relationship. In patients with diastol-
ic dysfunction, a small increase in end-diastolic volume may lead to an exaggerated increase 
in end-diastolic pressure, leading to an increase in left atrial and pulmonary capillary wedge 
pressure, causing pulmonary hypertension and symptoms of pulmonary congestion   [5]  . Fi-
nally, pulmonary hypertension can induce right-side heart failure and liver congestion. Sev-
eral authors   [6–8]   have observed that the liver function test profile typical of heart failure is 
a predominantly cholestatic profile with normal transaminase levels but with increased bil-
irubin,      -glutamyl transferase (GGT) and alkaline phosphatase (ALP).
  High levels of ALP have been associated with increased mortality in hemodialysis  [9, 10]  
and pre-dialysis   [11]   patients, suggesting that this association could be part of the novel as-
sociation between mineral and bone disease and mortality among patients with CKD   [12, 
13] . The authors highlighted that this association was independent of liver disease. However, 
as marker of liver disease only hepatitis C virus serology and transaminase levels were mea-
sured whereas cholestatic profile was not analyzed.
  We hypothesize that elevated ALP levels in patients with CKD could be partly explained 
by subclinical liver congestion related to LV diastolic dysfunction, hypervolemia or both con-
ditions which finally can induce pulmonary hypertension and subclinical right-side heart 
failure.
  Patients  and  Methods
    Sixty eight patients with CKD stages IV and V, followed in our single outpatient pre-
dialysis unit, were enrolled. Clearance of creatinine (CrCl) was measured using the 24-hour 
urine collection method.
    Demographic characteristics at the entry of the initial evaluation were recorded. Char-
acteristically, the patients enrolled in this study had low comorbidity as those patients with 
CKD and associated cardiopathy (ischemic or valvular cardiopathy) are usually followed in 
our special cardio-renal unit. Patients were followed up for a median of 2 years. Follow-up 
clinical and laboratory data recorded during follow-up in relation to outpatient visits were 
also extracted and utilized in time-varying analysis.
    Two-dimensional echocardiography was performed. LV diastolic function was as-
sessed using mitral valve inflow Doppler. LV filling pressure was assessed using the ratio 
of the peak early mitral inflow velocity (E) to medial mitral annular early diastolic veloc-
ity E    . LV filling pressure was considered to be elevated when E/E        1  10. Pulmonary hyper-
tension was calculated in those patients with tricuspid regurgitation using the Bernoulli 
equation   [14]  , measuring the pressure gradient between right ventricle and right atrium. 285
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Pulmonary hypertension was considered when pulmonary artery systolic pressure was 
higher than 30 mm Hg. Patients were evaluated monthly or every other month during a 
median follow-up period of 2.2 years. In each visit, patients were weighed and blood pres-
sure (BP) was measured using a standard mercury sphygmomanometer. Before each visit, 
blood samples were obtained from patients after overnight fasting. Blood hemoglobin 
(Hb), serum albumin, cholesterol, parathyroid hormone (PTH) and cholestatic profile 
markers (ALP and GGT) were measured by routine laboratory methods. A high-sensitivi-
ty assay for C-reactive protein (CRP) measurement was used. Serum CRP was measured 
by nephelometry on a BNA II (Dade Behring, Liederbach, Germany). N-terminal prohor-
mone of brain natriuretic peptide (NT-proBNP) was determined using chemiluminiscent 
Elecsys proBNP sandwich immunoassay (ECLIA) on an Elecsys 2010 (Roche Diagnostic, 
Mannheim, Germany). The levels of 25-OH vitamin D were determined by radioimmuno-
assay (Dia Sorin, Stillwater, Minn., USA). The treatment with vitamin D supplements was 
also recorded.
    Time-averaged clinical and laboratory data were compared between patients with and 
without elevated LV filling pressure and also between patients with and without pulmonary 
hypertension.
    In a second part of the study, we analyzed the possible effect on ALP levels of intensify-
ing diuretic treatment in a group of patients with high levels of ALP and signs of overhydra-
tion, even when these signs of overhydration were subclinical. Those patients who experi-
enced an increase in body weight in parallel with an increase in blood pressure values com-
pared to previous visits were considered as possibly overhydrated. We analyzed the possible 
variation in ALP levels in these patients after intensifying diuretic treatment. The analysis 
was made only in those patients who experienced a reduction in body weight and blood 
pressure in the subsequent visit. Finally, the analysis was made in a small subgroup of 16 
patients.
    Continuous data are expressed as mean   8   SD or median (interquartile range), depend-
ing on their distribution. Unpaired or paired t test was used for comparison of normally dis-
tributed variables. For variables with skewed distribution, the      2  test of the Fisher exact test 
was used. Correlation between continuous variables was assessed using the Pearson or Spear-
man correlation coefficient. A two-tailed p value   !  0.05 was considered statistically signifi-
cant. Data were performed using SPSS (version 12.0).
  R e s u l t s
    Demographic characteristics are expressed in   table 1  . As the patients were relatively old, 
vascular and diabetic nephropathy were the most frequent causes of CKD.
    Elevated LV filling pressure was observed in 49 (76%) of the patients. However, only 6 
patients (13%) showed echocardiographic data of pulmonary hypertension in addition to an 
increased LV filling pressure.
    Forty-six patients (74%) received supplements of vitamin D and in 15 patients an arte-
riovenous fistula was created during the follow-up.
    Time-averaged systolic BP levels and time-averaged levels of all the laboratory param-
eters measured during the study period are expressed in   table 2  . Time-averaged ALP corre-
lated significantly with GGT (r = 0.5; p  !   0.001) and inversely with serum albumin (r = –0.28; 
p = 0.04). The correlation between ALP and GGT is expressed in  figure 1 . No significant cor-
relation between ALP and PTH (p = 0.09) was found. ALP did not correlate significantly 
either with plasma levels of 25-OH vitamin D (p = 0.59) or systolic BP (p = 0.24), blood Hb 
(p = 0.14), CRP (p = 0.09), patient age (p = 0.23) or CrCl at baseline.286
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  ALP was higher in diabetic patients (97  8   42 U/l vs. 81  8   24 U/l in nondiabetic patients; 
p = 0.04), whereas no significant differences between genders (p = 0.1) was found. Time-av-
eraged ALP was not different (p = 0.49) between patients with or without an arteriovenous 
fistula.
    The differences in clinical and laboratory data between patients with and without an 
increased LV filling pressure are expressed in  table 3 . Patients with increased LV filling pres-
sure were older, showed higher levels of ALP and GGT and lower levels of serum albumin. 
Blood hemoglobin was lower in these patients although the difference did not reach statisti-
cal significance (p = 0.09). NT-proBNP was slightly higher, although the difference was also 
not significant (p = 0.6).
    The highest values of ALP were observed in those patients who showed pulmonary hy-
pertension in addition to an increased LV filling pressure. These patients also showed high-
er values of GGT and NT-proBNP. These results are expressed in   table 4  .
 Number  68 
 Age,  years  63813 
  Sex (men)  44 (69) 
  Basal CrCl, ml/min  2386 
  Causes of CKD 
 Vascular  20  (31) 
 Diabetes  19  (30) 
  Chronic GN  10 (16) 
 Interstitial  8  (12) 
 PCKD  3  (5) 
 Unknown  3  (5) 
 Others  1  (2) 
  Diastolic dysfunction  49 (76) 
  Pulmonary hypertension  6 (13) 
  Vitamin D supplements  46 (74) 
  Vascular access  15 (24) 
 Follow-up,  years   2.1  (1.2–2.3) 
  D  ata expressed as number (percentage), mean 8 SD or median 
(interquartile range). CrCl = Clearance of creatinine; CKD = chronic 
kidney disease; GN = glomerulonephritis; PCKD = polycystic kidney 
disease. 
 
 
  Table  1.  D  emographic 
  characteristics of the patients 
enrolled in the study
 
  Systolic BP, mm Hg  139811 
 ALP,  U/l  86831 
 GGT,  U/l  37829 
 PTH,  pg/ml  2918184 
244 (187–325) 
 Albumin,  g/dl  4.080.3 
 Cholesterol,  mg/dl  186832 
 Hemoglobin,  g/dl  12.680.6 
  C-reactive protein, mg/l  4 (2–8) 
 NT-proBNP,  pg/ml   1,33981,263 
  D  ata expressed as mean 8 SD or median (interquartile range). 
ALP = Alkaline phosphatase; GGT =  -glutamyl transferase; PTH = 
parathyroid hormone. 
 
 
  Table  2.  M  ean time-averaged 
values of systolic blood pressure 
(BP) and all the laboratory data 
measured during the study 
 period
 287
Nephron Extra 2011;1:283–291
 DOI:  10.1159/000335303 
EXTRA
  Ortega et al.: Alkaline Phosphatase and Diastolic Dysfunction 
www.karger.com/nne
  © 2012 S. Karger AG, Basel 
  Published online: January 18, 2012 
  Fi g .   1.   A significant correlation 
exists between     -glutamyl trans-
ferase and alkaline phosphatase 
(r = 0.5; p   !   0.001). 
 High  LVFP
  (n  =  46) 
 Normal  LVFP
  (n  =  22) 
 p  value 
 Age,  years  67815 64811   0.02 
 ALP,  U/l  91832 67815   0.01 
 GGT,  U/l  41828 2289   0.03 
 Albumin,  g/dl  4.080.2 4.180.2   0.04 
 PTH,  pg/ml  2958209 3028164   0.9 
  25-OH vitamin D, ng/ml  20810 22810   0.5 
 Cholesterol,  mg/dl  190833 171821   0.2 
 Hemoglobin,  g/dl  12.580.5 12.880.6   0.09 
  C-reactive protein, mg/l  6.684.9 4.883.1   0.8 
 NT-proBNP,  pg/ml   1,51181,472   1,20681,007   0.6 
  D  ata expressed as mean 8 SD. ALP = Alkaline phosphatase; 
GGT =  -glutamyl transferase; PTH = parathyroid hormone. 
 
 
 PH
  (n  =  6) 
 No  PH
  (n  =  62) 
 p  value 
 ALP,  U/l  103827 81830   0.04 
 GGT,  U/l  65847 30816   0.001 
 NT-proBNP,  pg/ml   3,05681,473   9378915   0.005 
  D  ata expressed as mean 8 SD. ALP = Alkaline phosphatase; 
GGT =  -glutamyl transferase; PTH = parathyroid hormone. 
 
 
  Table  4.  C  omparison of time-
averaged levels of ALP, GGT 
and NT-proBNP between 
  patients with and without 
  pulmonary hypertension (PH)
 
  Table  3.  C  omparison of 
  demographic and time-averaged 
laboratory parameters between 
patients with high or normal 
left ventricular filling pressure 
(LVFP)
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    Intensifying diuretic therapy in the subgroup of 16 patients with high levels of ALP and 
signs of fluid overload, even subclinical, induced a significant decrease in body weight of 1.8 
  8   0.9 kg (78  8   15 kg at baseline vs. 76  8   15 kg after intensifying diuretic therapy; p  !   0.001) 
as well as in systolic BP (from 146   8   18 mm Hg to 133   8   16 mm Hg; p   !   0.001) in the sub-
sequent visit. GGT levels also decreased significantly (from 100   8   52 U/l to 45   8   29 U/l;
p   !   0.001) as did ALP (from 112   8   49 U/l to 90   8   40 U/l; p   !   0.001). The variation in GGT 
and ALP levels after intensifying diuretic treatment is expressed in   figures 2   and   3  , respec-
tively.
  Discussion
    The main findings of our study are that ALP and GGT levels were higher in CKD pa-
tients with an increased LV filling pressure and especially in those patients who in addition 
showed evidence of pulmonary hypertension. Time- averaged ALP and GGT levels corre-
lated strongly with each other in our study.
    Volume overload control could reduce both ALP and GGT levels probably by reducing 
LV volume and, therefore, LV pressure in these patients with diastolic dysfunction. Thus, our 
results suggest that high ALP levels among patients with advanced renal failure could be part 
of the cholestatic profile related to subclinical liver congestion in patients with an increased 
LV filling pressure, in whom a small increment in LV volume can induce an exaggerated in-
crease in LV pressure which finally can induce pulmonary hypertension and right-side heart 
failure. The worse prognosis of CKD patients with high levels of ALP could therefore be ex-
plained by their myocardial damage.
  Fi g .  2 .   Variation of     -glutamyl transferase levels af-
ter intensifying diuretic therapy and achieving a 
mean body weight reduction of 1.8  8   0.9 kg (range: 
0.5–3.5 kg) in the subgroup of patients (n = 16) with 
higher levels of alkaline phosphatase (p   !   0.001). 
  Fi g .  3 .   Variation of alkaline phosphatase levels after 
intensifying diuretic therapy and achieving a mean 
body weight reduction of 1.8   8   0.9 kg (range: 0.5–
3.5 kg) in the subgroup of patients (n = 16) with 
higher levels of alkaline phosphatase (p   !   0.001). 289
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    The prevalence of LV hypertrophy in CKD patients is high, ranging from 34% to 78% in 
the different studies, with increased prevalence with declining renal function   [15, 16]  . Myo-
cardial fibrosis is also highly prevalent among patients with CKD   [17]   and it is determinant 
of diastolic dysfunction, which is the most frequent echocardiographic finding among pa-
tients with advanced renal failure   [4]   and occurs at the very early stages of CKD   [18]  .
    When diastolic dysfunction is present, a small increment in end-diastolic volume can 
induce an exaggerated increase in end-diastolic pressure related to the reduced LV distensi-
bility. This increase in LV filling pressure can induce elevated left atrial pressure with resul-
tant pulmonary congestion, elevated right atrial pressure and finally, systemic congestion  [4] . 
In this setting, liver congestion can occur with biochemical cholestatic profile and serum 
elevation of GGT and ALP.
    ALP is a hydrolase enzyme responsible for removing phosphate groups for many types 
of molecules. Elevated serum ALP levels are often observed in renal osteodystrophy, espe-
cially in high-turnover bone disease. Several authors   [9–11]   have observed that high levels of 
ALP predict mortality among patients with CKD, supporting the novel association between 
mineral and bone disease and mortality among patients with CKD. Although patients with 
higher levels of ALP showed higher levels of PTH, the authors highlight that high levels of 
ALP predict mortality after adjustment of calcium, phosphate and PTH. Furthermore, the 
death risk associated with higher ALP was increasing linearly, in opposition to an U-shaped 
relationship found between PTH and mortality.
    There is mounting evidence that alkaline phosphatase can promote vascular calcifica-
tion by hydrolyzing pyrophosphate in the arterial wall   [19]  . Thus, the authors suggest pro-
gressive vascular calcification as a possible underlying mechanism explaining the associa-
tion between ALP levels and mortality.
    However, serum ALP may also increase as a result of liver disorders. In the previous 
studies  [9–11] , the mortality risk of high ALP levels was maintained independent of liver dis-
ease. However, as marker of liver disease only transaminases and serological markers were 
analyzed, whereas cholestatic profile was not measured. In another study performed in pa-
tients with reduced GFR between 20 and 65 ml/min, Beddhu and colleagues  [20]  determined 
not only transaminase levels but also bilirubin and GGT levels in their patients. They ob-
served no significant differences across the alkaline phosphatase group regarding serum 
calcium and phosphorus as well as serum aspartate aminotransferase, alanine aminotrans-
ferase and bilirubin. However, the high alkaline phosphatase group had higher GGT levels. 
In this study, after adjusting for liver function tests, high serum alkaline phosphatase was 
not associated with increased mortality in the first 2 years of follow-up, but was associated 
with increased mortality after 2 years of follow-up.
    In the present study, we found a strong correlation between time-averaged ALP and 
GGT in our patients. On the contrary, no significant association between ALP and PTH was 
found. This is not a surprising finding as most of our patients received vitamin D supple-
ments, and a recent meta-analysis showed that the treatment of renal osteodystrophy by 
means of vitamin D analogs can effectively decrease ALP levels, even though such a treat-
ment may not decrease PTH consistently   [21]  . Thus, it seems that high ALP levels are main-
ly related to liver disorders in these patients in whom renal osteodystrophy is treated. As both 
ALP and GGT were higher in patients with increased LV filling pressure and especially in 
those patients with pulmonary hypertension, we could hypothesize that subclinical liver 
congestion could explain the biochemical cholestatic profile. Furthermore, the control of 
volume overload by intensifying diuretic therapy could reduce ALP and GGT levels in our 
patients, probably by reducing LV volume and pressure.
    Serum alkaline phosphatase has been associated with elevated CRP levels   [22]   and high 
levels of CRP have been also associated with an increased LV filling pressure among patients 290
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with CKD   [23–25]  . This association supports our hypothesis that high ALP levels are main-
ly of liver origin among patients with CKD. In patients with diastolic dysfunction, overhy-
dration increases LV pressure, finally leading to an increased right-side pressure and hepat-
ic congestion. Right-side heart failure can also induce systemic inflammation. The hypoth-
esis supporting this association between heart failure and inflammation has been proposed 
several years ago. Niebauer et al.   [26]   suggested that during acute cardiac decompensation, 
acute venous mesenteric venous congestion with subsequent altered gut permeability for en-
dotoxins would lead to translocation of these materials into the circulation, inducing the 
inflammatory response. However, in our study, CRP was higher, although not significant, in 
those patients with increased LV filling pressure, although no patients showed evident clin-
ical signs of heart failure. There was a trend to correlation between ALP and CRP in our pa-
tients, although it did not reach statistical signification.
    The major limitation of our study is that it is a small study including a small number of 
patients with advanced CKD followed at a single center. Another limitation is that serum 
calcium and phosphorus levels were not recorded. However, this limitation does not invali-
date our results suggesting that liver disease, probably liver congestion, could be the main 
source of serum ALP among patients with advanced renal failure.
    In summary, in the present study we found a strong correlation between ALP and GGT 
levels among patients with advanced CKD, whereas the correlation with PTH was not sig-
nificant. Both parameters, ALP and GGT, were higher in those patients with increased LV 
filling pressure and, especially in patients with pulmonary hypertension, suggesting that 
liver congestion and not mineral and bone disease could be the main source of high levels of 
ALP in these patients. Furthermore, control of volume overload could reduce ALP and GGT 
probably by reducing LV volume and, therefore, LV pressure. Thus, our results suggest that 
the worse prognosis of CKD patients with high levels of ALP could be related to their myo-
cardial damage. Further studies are required in order to analyze whether reduction of ALP 
by a strategy of strict volume control could improve the prognosis of CKD patients with high 
levels of alkaline phosphatase.
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